Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03392974 · ClinicalTrials.gov registry record · Phase 3
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg
A Phase 3 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT03392974 is a Phase 3 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 1 participants.
The verdict
NCT03392974, a Phase 3 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
This Phase III clinical study will assess the efficacy of BMN 270 defined as FVIII activity, during weeks 49-52 following intravenous infusion of BMN 270 and assess the impact of BMN 270 on usage of exogenous FVIII replacement therapy and the number of bleeding episodes from week 5 to week 52.
Interventions
- BIOLOGICAL Valoctocogene Roxaparvovec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-03-14 |
| Est. Completion | 2023-06-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03392974
The ClinicalTrials.gov registry entry for NCT03392974 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valoctocogene Roxaparvovec is the first listed.
NCT03392974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03392974 about?
NCT03392974 is a clinical study titled "Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg". This Phase III clinical study will assess the efficacy of BMN 270 defined as FVIII activity, during weeks 49-52 following intravenous infusion of BMN 270 and assess the impact of BMN 270 on usage of exogenous FVIII replacement therapy and the number of bleeding episodes from week 5 to week 52.
What is the current status of trial NCT03392974?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2018-03-14. Estimated completion is 2023-06-05.
What interventions are being tested in trial NCT03392974?
The interventions under investigation include: Valoctocogene Roxaparvovec (BIOLOGICAL).
Who is sponsoring clinical trial NCT03392974?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.